Switch theme
Sign up to access all valuation multiples
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
2006
15
LTM Revenue n/a
LTM EBITDA n/a
$90.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
SELLAS Life Sciences has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, SELLAS Life Sciences achieved revenue of n/a and an EBITDA of -$31.5M.
SELLAS Life Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See SELLAS Life Sciences valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | $0.9M | n/a | XXX | XXX | XXX |
| Gross Margin | Infinity% | NaN% | XXX | XXX | XXX |
| EBITDA | -$37.9M | -$31.5M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$41.3M | -$37.3M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, SELLAS Life Sciences's stock price is $1.
SELLAS Life Sciences has current market cap of $104M, and EV of $90.7M.
See SELLAS Life Sciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $90.7M | $104M | XXX | XXX | XXX | XXX | $-0.48 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, SELLAS Life Sciences has market cap of $104M and EV of $90.7M.
SELLAS Life Sciences's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate SELLAS Life Sciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for SELLAS Life Sciences and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $90.7M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -2.9x | XXX | XXX | XXX |
| P/E | -3.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -2.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSELLAS Life Sciences's NTM/LTM revenue growth is n/a
SELLAS Life Sciences's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $2.1M for the same period.
Over next 12 months, SELLAS Life Sciences's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate SELLAS Life Sciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for SELLAS Life Sciences and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -17% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $2.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SELLAS Life Sciences acquired XXX companies to date.
Last acquisition by SELLAS Life Sciences was XXXXXXXX, XXXXX XXXXX XXXXXX . SELLAS Life Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was SELLAS Life Sciences founded? | SELLAS Life Sciences was founded in 2006. |
| Where is SELLAS Life Sciences headquartered? | SELLAS Life Sciences is headquartered in United States of America. |
| How many employees does SELLAS Life Sciences have? | As of today, SELLAS Life Sciences has 15 employees. |
| Who is the CEO of SELLAS Life Sciences? | SELLAS Life Sciences's CEO is Dr. Angelos M. Stergiou, M.D.. |
| Is SELLAS Life Sciences publicy listed? | Yes, SELLAS Life Sciences is a public company listed on NAS. |
| What is the stock symbol of SELLAS Life Sciences? | SELLAS Life Sciences trades under SLS ticker. |
| When did SELLAS Life Sciences go public? | SELLAS Life Sciences went public in 2008. |
| Who are competitors of SELLAS Life Sciences? | Similar companies to SELLAS Life Sciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of SELLAS Life Sciences? | SELLAS Life Sciences's current market cap is $104M |
| Is SELLAS Life Sciences profitable? | Yes, SELLAS Life Sciences is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
